InterAx Biotech AG, a spin-off company of the Paul Scherrer Institute and ETH, is setting new standards in drug development with its advanced AI platform. By uncovering novel cellular signalling pathways, the company is paving the way for innovative therapies in the fields of diabetes, obesity and immuno-oncology.